Evidence map›Paper›PMID 40690206›Full record

ArticleJournal of proteome research2025

OCIAD2 Promotes Cancer Progression via Metabolic Reprogramming in Lung Adenocarcinoma.

Yi-Hui Huang, Wen-Hsin Chang, Chi-Ya Shen, Kang-Yi Su, Gee-Chen Chang, Jin-Shing Chen, Wen-Yao Lee, Yu-Ju Chen, Sung-Liang Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Hui HuangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10048, Taiwan.ORCID 0009-0001-8887-0902
Wen-Hsin ChangGraduate Institute of Medical Science, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-8027-302X
Chi-Ya ShenDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10048, Taiwan.ORCID 0000-0002-2593-7356
Kang-Yi SuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10048, Taiwan.
Gee-Chen ChangDepartment of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
Jin-Shing ChenDepartment of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Wen-Yao LeeDepartment of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Yu-Ju ChenInstitute of Chemistry, Academia Sinica, Taipei 11529, Taiwan.ORCID 0000-0002-3178-6697
Sung-Liang YuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10048, Taiwan.ORCID 0000-0003-4535-9036

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the limited proteomic insights and high incidence of lung adenocarcinoma, further investigation of uncharacterized proteins in cancer progression remains crucial. In this study, a poorly characterized protein, OCIA domain-containing 2 (OCIAD2), encoded by chromosome 4 was identified as being upregulated in lung adenocarcinoma from our previous proteogenomics data using the Taiwan Cancer Moonshot cohort. OCIAD2 was highly expressed in tumor tissues in 95.5% of lung adenocarcinoma patients in our cohort, with elevated expression correlating with worse survival. Functional studies revealed that the silencing of the OCIAD2 decreased cell migration, invasion, and colony-forming abilities. Gene Set Enrichment Analysis (GSEA) indicated the involvement of OCIAD2 in oxidative phosphorylation (OXPHOS). Subsequently, mitochondrial metabolic assay demonstrated that OCIAD2 impairs OXPHOS function, accompanied by a metabolic shift toward glycolysis. These findings suggest that OCIAD2 promotes cancer progression through metabolic reprogramming, highlighting the role of OCIAD2 as a potential biomarker and therapeutic target for lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungLung NeoplasmsBiomarkers, TumorCell Line, TumorCell MovementDisease ProgressionFemaleGene Expression Regulation, NeoplasticGlycolysisHumansMaleMetabolic ReprogrammingMitochondriaOxidative PhosphorylationBiomarkers, TumorChromosome-centric Human Proteome ProjectLung adenocarcinomaOvarian Cancer Immunoreactive Antigen Domain Containing 2Uncharacterized protein existence level 1

Identifiers

PMID40690206
PMCPMC12323000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.